Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))

W. W. Tan; D. W. Hillman; M. Salim; D. W. Northfelt; D. M. Anderson; P. J. Stella; R. Niedringhaus; A. M. Bernath; S. S. Gamini; F. Palmieri; E. A. Perez

doi:10.1093/annonc/mdx811

Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))

W. W. Tan
, D. W. Hillman
, M. Salim
, D. W. Northfelt
, D. M. Anderson
, P. J. Stella
, R. Niedringhaus
, A. M. Bernath
, S. S. Gamini
, F. Palmieri
, E. A. Perez

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Ann Oncol 2010; 21: 493–497 (doi: 10.1093/annonc/mdp328) The following funding statement was missing from the original manuscript: ‘Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.’ This has now been amended in the online version.

Original language	English (US)
Pages (from-to)	2150
Number of pages	1
Journal	Annals of Oncology
Volume	29
Issue number	10
DOIs	https://doi.org/10.1093/annonc/mdx811
State	Published - Oct 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdx811

Fingerprint

Dive into the research topics of 'Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))'. Together they form a unique fingerprint.

Cite this

Tan, W. W., Hillman, D. W., Salim, M., Northfelt, D. W., Anderson, D. M., Stella, P. J., Niedringhaus, R., Bernath, A. M., Gamini, S. S., Palmieri, F., & Perez, E. A. (2018). Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328)). Annals of Oncology, 29(10), 2150. https://doi.org/10.1093/annonc/mdx811

Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328)). / Tan, W. W.; Hillman, D. W.; Salim, M. et al.
In: Annals of Oncology, Vol. 29, No. 10, 10.2018, p. 2150.

Research output: Contribution to journal › Comment/debate › peer-review

Tan, WW, Hillman, DW, Salim, M, Northfelt, DW, Anderson, DM, Stella, PJ, Niedringhaus, R, Bernath, AM, Gamini, SS, Palmieri, F & Perez, EA 2018, 'Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))', Annals of Oncology, vol. 29, no. 10, pp. 2150. https://doi.org/10.1093/annonc/mdx811

Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ et al. Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328)). Annals of Oncology. 2018 Oct;29(10):2150. doi: 10.1093/annonc/mdx811

Tan, W. W. ; Hillman, D. W. ; Salim, M. et al. / Correction to : N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328)). In: Annals of Oncology. 2018 ; Vol. 29, No. 10. pp. 2150.

@article{02b7dfe63f5c4253a714a6281ffce9af,

title = "Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))",

abstract = "Ann Oncol 2010; 21: 493–497 (doi: 10.1093/annonc/mdp328) The following funding statement was missing from the original manuscript: {\textquoteleft}Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.{\textquoteright} This has now been amended in the online version.",

author = "Tan, \{W. W.\} and Hillman, \{D. W.\} and M. Salim and Northfelt, \{D. W.\} and Anderson, \{D. M.\} and Stella, \{P. J.\} and R. Niedringhaus and Bernath, \{A. M.\} and Gamini, \{S. S.\} and F. Palmieri and Perez, \{E. A.\}",

note = "Publisher Copyright: {\textcopyright} 2018 THE AUTHORS",

year = "2018",

month = oct,

doi = "10.1093/annonc/mdx811",

language = "English (US)",

volume = "29",

pages = "2150",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "10",

}

TY - JOUR

T1 - Correction to

T2 - N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))

AU - Tan, W. W.

AU - Hillman, D. W.

AU - Salim, M.

AU - Northfelt, D. W.

AU - Anderson, D. M.

AU - Stella, P. J.

AU - Niedringhaus, R.

AU - Bernath, A. M.

AU - Gamini, S. S.

AU - Palmieri, F.

AU - Perez, E. A.

PY - 2018/10

Y1 - 2018/10

N2 - Ann Oncol 2010; 21: 493–497 (doi: 10.1093/annonc/mdp328) The following funding statement was missing from the original manuscript: ‘Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.’ This has now been amended in the online version.

AB - Ann Oncol 2010; 21: 493–497 (doi: 10.1093/annonc/mdp328) The following funding statement was missing from the original manuscript: ‘Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.’ This has now been amended in the online version.

UR - https://www.scopus.com/pages/publications/85045123937

UR - https://www.scopus.com/pages/publications/85045123937#tab=citedBy

U2 - 10.1093/annonc/mdx811

DO - 10.1093/annonc/mdx811

M3 - Comment/debate

C2 - 29390054

AN - SCOPUS:85045123937

SN - 0923-7534

VL - 29

SP - 2150

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -

Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this